asap

[ASAP] Peptoid NPhe<sup>4</sup> in AGRP-Based c[Pro<sup>1</sup>-Arg<sup>2</sup>-Phe<sup>3</sup>-Phe<sup>4</sup>-Xxx<sup>5</sup>-Ala<sup>6</sup>-Phe<sup>7</sup>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00641




asap

[ASAP] Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00075




asap

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




asap

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




asap

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




asap

[ASAP] Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00041




asap

[ASAP] Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-Dimensional Character

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00039




asap

[ASAP] Characterization of an Alginate Encapsulated LS180 Spheroid Model for Anti-colorectal Cancer Compound Screening

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00076




asap

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




asap

[ASAP] Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00625




asap

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




asap

[ASAP] Assembling Pharma Resources to Tackle Diseases of Underserved Populations

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00051




asap

[ASAP] Pharmacophore-Based Virtual Screening for Identification of Negative Modulators of GLI1 as Potential Anticancer Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00639




asap

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




asap

[ASAP] Discovery of BMS-986251: A Clinically Viable, Potent, and Selective ROR?t Inverse Agonist

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00063




asap

[ASAP] Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00594




asap

[ASAP] New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00561




asap

[ASAP] Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00129




asap

[ASAP] Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00574




asap

[ASAP] Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00438




asap

[ASAP] Potential Cancer Treatment by Agonists of the Stimulator of Interferon Genes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00117




asap

[ASAP] Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00131




asap

[ASAP] Complete Regression of Carcinoma via Combined C-RAF and EGFR Targeted Therapy

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00159




asap

[ASAP] Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00008




asap

[ASAP] Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00661




asap

[ASAP] Characterization of Specific <italic toggle="yes">N</italic>-a-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00029




asap

[ASAP] Discovery of an Atropisomeric PI3Kß Selective Inhibitor through Optimization of the Hinge Binding Motif

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00095




asap

[ASAP] Can Drug Repositioning Work as a Systematical Business Model?

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00122




asap

[ASAP] Update to Our Reader, Reviewer, and Author Communities—April 2020

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00206




asap

[ASAP] Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00155




asap

[ASAP] PROTAC Compounds Targeting a-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer’s and Parkinson’s Diseases

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00192




asap

[ASAP] Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from <italic toggle="yes">Trypanosoma cruzi</italic>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00106




asap

[ASAP] P2Y<sub>14</sub> Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00115




asap

[ASAP] Discovery of RO7185876, a Highly Potent ?-Secretase Modulator (GSM) as a Potential Treatment for Alzheimer’s Disease

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00109




asap

[ASAP] Ultra-High-Throughput Acoustic Droplet Ejection-Open Port Interface-Mass Spectrometry for Parallel Medicinal Chemistry

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00066




asap

[ASAP] Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00025




asap

[ASAP] Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00092




asap

[ASAP] Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 d Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00028




asap

[ASAP] Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00009




asap

[ASAP] Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00085




asap

[ASAP] De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00022




asap

[ASAP] Synthesis and Evaluation of <sup>11</sup>C- and <sup>18</sup>F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00127




asap

[ASAP] Ligand Design for Cereblon Based Immunomodulatory Therapy

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00214




asap

[ASAP] Structural and Biological Basis of Small Molecule Inhibition of <italic toggle="yes">Escherichia coli</italic> LpxD Acyltransferase Essential for Lipopolysaccharide Biosynthesis

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00127




asap

[ASAP] Pyrimidine Analogues as a New Class of Gram-Positive Antibiotics, Mainly Targeting Thymineless-Death Related Proteins

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00305




asap

[ASAP] Potentiation of Antibiotics against Gram-Negative Bacteria by Polymyxin B Analogue SPR741 from Unique Perturbation of the Outer Membrane

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00159




asap

[ASAP] Substrate Tolerance of Bacterial Glycosyltransferase MurG: Novel Fluorescence-Based Assays

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00242




asap

[ASAP] Broad Spectrum ß-Lactamase Inhibition by a Thioether Substituted Bicyclic Boronate

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00330




asap

[ASAP] Antibacterial Photodynamic Inactivation of Antibiotic-Resistant Bacteria and Biofilms with Nanomolar Photosensitizer Concentrations

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.9b00379




asap

[ASAP] Multitarget Approaches against Multiresistant Superbugs

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.0c00001